5 TIPS ABOUT SIFALIMUMAB YOU CAN USE TODAY

MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine to evaluate a number of intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Key trial objectives ended up to evaluate the protection and tolerability of sifalimumab in dermatomyositis or poly